Is It Time to Stop Selling a Product? Here Are 3 Key Questions You Need to Ask to Unlock Longterm Profitability

Recent concerns for pharmaceutical companies have centered on President Trump's plans to reduce drug prices and impose tariffs on imports, causing investor hesitation. However, Pfizer became the first drugmaker to secure a pricing agreement with Trump, gaining a three-year exemption from import tariffs, which led to a 14% surge in its stock over two trading sessions. Want More Context? 🔎

CoreWeave (NASDAQ: CRWV), an AI cloud infrastructure company that transitioned from crypto mining, reported a remarkable 206% revenue increase to $1.21 billion in Q2, driven by the surging demand for AI computing power from clients like Microsoft, Nvidia, and OpenAI. The stock soared 12% after announcing a significant new deal with Meta Platforms (NASDAQ: META), further boosting its growth prospects. Want More Context? 🔎

Shares of D-Wave Quantum (NYSE: QBTS) surged 14% on Thursday, contrasting with a flat S&P 500 and a 0.4% gain in the Nasdaq Composite. This increase followed Rigetti Computing's announcement of selling two Novera quantum systems for a combined $5.7 million, signaling a positive outlook for the quantum market and boosting investor confidence in D-Wave. Want More Context? 🔎

Nike (NYSE: NKE) is showing signs of recovery, reporting a slight revenue growth in Q1 of fiscal 2026 after challenging periods, with shares rising as investor confidence in new leadership grows. Despite progress in key categories, concerns about competitive pressures and margins persist, and the stock may not be considered cheap given its recent performance. Want More Context? 🔎

Shares of AstraZeneca (NASDAQ: AZN) surged over 10% this week following positive clinical results for Enhertu in HER2-positive breast cancer and a significant deal between Pfizer (NYSE: PFE) and the Trump administration, where Pfizer will reduce drug prices and invest $70 billion domestically, gaining a three-year exemption from tariffs on pharmaceutical imports. This agreement was highlighted during a press conference with Pfizer CEO Albert Bourla and President Trump. Want More Context? 🔎

Shares of Carnival (NYSE: CCL) dipped despite a strong Q3 earnings report, with revenue rising 3.3% to $8.15 billion and adjusted net income improving to $1.98 billion, surpassing estimates. The company raised its guidance for the year, projecting a 55% increase in adjusted net income to $2.95 billion and a 15% rise in adjusted EBITDA to $7.05 billion, driven by higher net yields and cost management. Want More Context? 🔎